Venous thromboembolism and cancer: A systematic review

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 1, 2010, Pages 67-78

  Rodrigues, Celso Arrais ^a   Ferrarotto, Renata ^a   Filho, Roberto Kalil ^a   Novis, Yana A S ^a   Hoff, Paulo M G ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

Anticoagulation; Cancer; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTIANEMIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTIVITAMIN K; APIXABAN; BEVACIZUMAB; CYTOKINE; DABIGATRAN; DALTEPARIN; DEXAMETHASONE; DOXORUBICIN; ENOXAPARIN; ERLOTINIB; ERYTHROPOIETIN; FONDAPARINUX; GEMCITABINE; HEPARIN; HEPARIN DERIVATIVE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; NADROPARIN; PLACEBO; PLATINUM COMPLEX; RIVAROXABAN; STEROID; THALIDOMIDE; UNINDEXED DRUG; VORINOSTAT; WARFARIN; POLYSACCHARIDE;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CANCER CELL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; COMORBIDITY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISEASE COURSE; FIBRINOLYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; HYPERCOAGULABILITY; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LOW DRUG DOSE; MAJOR SURGERY; MALIGNANT NEOPLASTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; THROMBOSIS; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; COMPLICATION; NEOPLASMS;

HEPARIN; HUMANS; NEOPLASMS; POLYSACCHARIDES; QUALITY OF LIFE; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 77953870495     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-010-0441-0     Document Type: Review

References (115)

1. Trousseau A (1865) Phlegmasia alba dolens, 2nd edn. JB Balliere et Fils, Paris
2. AA Khorana SA Ahrendt CK Ryan, et al. 2007 Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer Clin Cancer Res 13 2870 2875 1:CAS:528:DC%2BD2sXlt1KrsrY%3D 17504985
3. AY Lee MN Levine 2003 Venous thromboembolism and cancer: risks and outcomes Circulation 107 I17 I21 12814981
4. RH White HK Chew H Zhou, et al. 2005 Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults Arch Intern Med 165 1782 1787 16087828
5. P Prandoni A Piccioli 1997 Venous thromboembolism and cancer: a two-way clinical association Front Biosci 2 e12 e20 1:STN:280:DC%2BD2czktVGjtQ%3D%3D 9159235
6. RL Bick 1978 Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management Semin Thromb Hemost 5 1 26 1:STN:280:DyaE1M%2FjsFCntg%3D%3D 705351
7. AK Kakkar M Levine HM Pinedo, et al. 2003 Venous thrombosis in cancer patients: insights from the FRONTLINE survey Oncologist 8 381 388 12897335
8. N Levitan A Dowlati SC Remick, et al. 1999 Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data Medicine (Baltimore) 78 285 291 1:STN:280:DyaK1MvivVymug%3D%3D
9. HT Sorensen L Mellemkjaer JH Olsen, et al. 2000 Prognosis of cancers associated with venous thromboembolism N Engl J Med 343 1846 1850 1:STN:280:DC%2BD3M%2FmsVyjuw%3D%3D 11117976
10. PD Stein A Beemath FA Meyers, et al. 2006 Incidence of venous thromboembolism in patients hospitalized with cancer Am J Med 119 60 68 16431186 (Pubitemid 43117468)
11. JW Blom CJ Doggen S Osanto, et al. 2005 Malignancies, prothrombotic mutations, and the risk of venous thrombosis JAMA 293 715 722 1:CAS:528:DC%2BD2MXhtFeltL8%3D 15701913 (Pubitemid 40216041)
12. O Huber H Bounameaux F Borst, et al. 1992 Postoperative pulmonary embolism after hospital discharge. An underestimated risk Arch Surg 127 310 313 1:STN:280:DyaK387pvVajsw%3D%3D 1550477
13. AK Kakkar S Haas H Wolf, et al. 2005 Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy Thromb Haemost 94 867 871 1:CAS:528:DC%2BD2MXhtF2it7nJ 16270644
14. AA Khorana CW Francis E Culakova, et al. 2006 Thromboembolism in hospitalized neutropenic cancer patients J Clin Oncol 24 484 490 16421425
15. P Prandoni A Falanga A Piccioli 2005 Cancer and venous thromboembolism Lancet Oncol 6 401 410 15925818
16. JA Baron G Gridley E Weiderpass, et al. 1998 Venous thromboembolism and cancer Lancet 351 1077 1080 1:STN:280:DyaK1czit1SisA%3D%3D 9660575
17. HT Sorensen L Mellemkjaer FH Steffensen, et al. 1998 The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism N Engl J Med 338 1169 1173 1:STN:280:DyaK1c3gvFGhsg%3D%3D 9554856
18. JT Murchison L Wylie DL Stockton 2004 Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study Br J Cancer 91 92 95 1:STN:280:DC%2BD2czitlOqtA%3D%3D 15226761
19. MJ Johnson MW Sproule J Paul 1999 The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer Clin Oncol (R Coll Radiol) 11 105 110 1:STN:280:DyaK1MzgsV2rsw%3D%3D
20. E Sproul 1938 Carcinoma and venous thrombosis: the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis Am J Cancer 34 566 585
21. JL Ambrus CM Ambrus J Pickern, et al. 1975 Hematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis J Med 6 433 458 1:STN:280:DyaE287ksV2mtg%3D%3D 130433
22. HT Sorensen L Pedersen L Mellemkjaer, et al. 2005 The risk of a second cancer after hospitalisation for venous thromboembolism Br J Cancer 93 838 841 1:STN:280:DC%2BD2MrlsFSgsw%3D%3D 16136048
23. S Schulman P Lindmarker 2000 Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial N Engl J Med 342 1953 1958 1:STN:280:DC%2BD3czit1arsQ%3D%3D 10874063
24. V Tagalakis H Tamim M Blostein, et al. 2007 Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study Lancet Oncol 8 395 402 1:CAS:528:DC%2BD2sXkslKru7o%3D 17466896
25. A Lazo-Langner GD Goss JN Spaans, et al. 2007 The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials J Thromb Haemost 5 729 737 1:CAS:528:DC%2BD2sXltlWgtrw%3D 17408406
26. M Altinbas HS Coskun O Er, et al. 2004 A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer J Thromb Haemost 2 1266 1271 1:CAS:528:DC%2BD2cXns1aisrs%3D 15304029
27. AK Kakkar MN Levine Z Kadziola, et al. 2004 Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) J Clin Oncol 22 1944 1948 1:CAS:528: DC%2BD2cXptlCks74%3D 15143088
28. CP Klerk SM Smorenburg HM Otten, et al. 2005 The effect of low molecular weight heparin on survival in patients with advanced malignancy J Clin Oncol 23 2130 2135 1:CAS:528:DC%2BD2MXjsVyiurY%3D 15699479
29. A Lee M Levine 2005 Treatment of venous thromboembolism in cancer patients Cancer Control 12 Suppl 1 17 21 16179900
30. TS Edgington N Mackman K Brand, et al. 1991 The structural biology of expression and function of tissue factor Thromb Haemost 66 67 79 1:CAS:528:DyaK38Xks12g 1833852
31. Y Nemerson 1995 Tissue factor: then and now Thromb Haemost 74 180 184 1:CAS:528:DyaK2MXnvVSrur0%3D 8578454
32. C Lopez-Pedrera N Barbarroja G Dorado, et al. 2006 Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies Leukemia 20 1331 1340 1:CAS:528:DC%2BD28XntVWlurs%3D 16728982
33. A Varki 2007 Trousseau's syndrome: multiple definitions and multiple mechanisms Blood 110 1723 1729 1:CAS:528:DC%2BD2sXhtVGjtLfJ 17496204
34. P Czaykowski D Hui 2007 Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency Clin Oncol (R Coll Radiol) 19 143 149 1:STN:280:DC%2BD2s7lsFGgsQ%3D%3D
35. KD Miller CJ Sweeney GW Sledge Jr 2001 Redefining the target: chemotherapeutics as antiangiogenics J Clin Oncol 19 1195 1206 1:CAS:528:DC%2BD3MXhvFertrY%3D 11181686
36. R Baz L Li K Kottke-Marchant, et al. 2005 The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma Mayo Clin Proc 80 1568 1574 1:CAS:528:DC%2BD2MXhtlelu7jF 16342649
37. M Zangari F Elice L Fink, et al. 2007 Thrombosis in multiple myeloma Expert Rev Anticancer Ther 7 307 315 1:CAS:528:DC%2BD2sXis1antL8%3D 17338651
38. T Sousou A Khorana 2009 Identifying cancer patients at risk for venous thromboembolism Hamostaseologie 29 121 124 1:STN:280:DC%2BD1M%2FotFCmtw%3D%3D 19151861
39. SW Yusuf P Razeghi ET Yeh 2008 The diagnosis and management of cardiovascular disease in cancer patients Curr Probl Cardiol 33 163 196 18319102
40. G Agnelli G Bolis L Capussotti, et al. 2006 A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project Ann Surg 243 89 95 16371741
41. J Lin TW Wakefield PK Henke 2006 Risk factors associated with venous thromboembolic events in patients with malignancy Blood Coagul Fibrinolysis 17 265 270 16651868
42. HK Chew T Wun D Harvey, et al. 2006 Incidence of venous thromboembolism and its effect on survival among patients with common cancers Arch Intern Med 166 458 464 16505267
43. AO Rodriguez T Wun H Chew, et al. 2007 Venous thromboembolism in ovarian cancer Gynecol Oncol 105 784 790 17408726
44. C Fotopoulou A duBois AN Karavas, et al. 2008 Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel- containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group J Clin Oncol 26 2683 2689 1:CAS:528:DC%2BD1cXnvVOhsLY%3D 18509180
45. HK Chew T Wun DJ Harvey, et al. 2007 Incidence of venous thromboembolism and the impact on survival in breast cancer patients J Clin Oncol 25 70 76 17194906
46. A Alcalay T Wun V Khatri, et al. 2006 Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival J Clin Oncol 24 1112 1118 16505431 (Pubitemid 46638808)
47. HK Chew AM Davies T Wun, et al. 2008 The incidence of venous thromboembolism among patients with primary lung cancer J Thromb Haemost 6 601 608 1:STN:280:DC%2BD1c7nvFKmsw%3D%3D 18208538
48. E Ramacciotti N Wolosker P Puech-Leao, et al. 2003 Prevalence of factor V Leiden, FII G20210A, FXIII Val34Leu and MTHFR C677T polymorphisms in cancer patients with and without venous thrombosis Thromb Res 109 171 174 1:CAS:528:DC%2BD3sXjvFekt7g%3D 12757770
49. M Kennedy AC Andreescu MS Greenblatt, et al. 2005 Factor V Leiden, prothrombin 20210A and the risk of venous thrombosis among cancer patients Br J Haematol 128 386 388 1:CAS:528:DC%2BD2MXitFOhu7c%3D 15667542
50. K Kröger D Weiland C Ose, et al. 2006 Risk factors for venous thromboembolic events in cancer patients Ann Oncol 17 297 303 16282243
51. MM Samama 2000 An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study Arch Intern Med 160 3415 3420 1:STN:280:DC%2BD3M%2FnvVeltA%3D%3D 11112234
52. P Prandoni AW Lensing A Cogo, et al. 1996 The long-term clinical course of acute deep venous thrombosis Ann Intern Med 125 1 7 1:STN:280: DyaK283ksFSktw%3D%3D 8644983
53. S Sallah JY Wan NP Nguyen 2002 Venous thrombosis in patients with solid tumors: determination of frequency and characteristics Thromb Haemost 87 575 579 1:CAS:528:DC%2BD38Xjt1egt7o%3D 12008937
54. JA Heit MD Silverstein DN Mohr, et al. 2000 Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study Arch Intern Med 160 809 815 1:STN:280:DC%2BD3c7pvFGnsw%3D%3D 10737280
55. JA Heit WM O'Fallon TM Petterson, et al. 2002 Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study Arch Intern Med 162 1245 1248 12038942
56. N Goldschmidt E Linetsky E Shalom, et al. 2003 High incidence of thromboembolism in patients with central nervous system lymphoma Cancer 98 1239 1242 12973848
57. JW Blom JP Vanderschoot MJ Oostindier, et al. 2006 Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study J Thromb Haemost 4 529 535 1:STN:280:DC%2BD28%2Fns1ertA%3D%3D 16460435
58. KI Pritchard AH Paterson NA Paul, et al. 1996 Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group J Clin Oncol 14 2731 2737 1:CAS:528:DyaK28XmsFCgt78%3D 8874334
59. A Palumbo SV Rajkumar MA Dimopoulos, et al. 2008 Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma Leukemia 22 414 423 1:CAS:528:DC%2BD1cXhvVyltLc%3D 18094721
60. AA Khorana CW Francis E Culakova, et al. 2007 Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J Thromb Haemost 5 632 634 1:STN:280:DC%2BD2s7itFCrtQ%3D%3D 17319909
61. B Fisher J Dignam N Wolmark, et al. 1997 Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer J Natl Cancer Inst 89 1673 1682 1:CAS:528:DyaK2sXnslyitbs%3D 9390536
62. SR Deitcher MP Gomes 2004 The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review Cancer 101 439 449 15274057
63. RC Coombes E Hall LJ Gibson, et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092 1:CAS:528:DC%2BD2cXitV2qtbc%3D 15014181 (Pubitemid 38298988)
64. SV Rajkumar MA Gertz MQ Lacy, et al. 2003 Thalidomide as initial therapy for early-stage myeloma Leukemia 17 775 779 1:CAS:528:DC%2BD3sXis12isb4%3D 12682636
65. SV Rajkumar E Blood D Vesole R Fonseca PR Greipp Eastern Cooperative Oncology Group 2006 Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group J Clin Oncol 24 3 431 436 1:CAS:528:DC%2BD28XhsFSku7s%3D 16365178
66. SV Rajkumar L Rosiñol M Hussein J Catalano W Jedrzejczak L Lucy M Olesnyckyj Z Yu R Knight JB Zeldis J Bladé 2008 Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma J Clin Oncol 26 13 2171 2177 1:CAS:528:DC%2BD1cXms1OrtLs%3D 18362366
67. F Kabbinavar HI Hurwitz L Fehrenbacher, et al. 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 1:CAS:528:DC%2BD2cXpsVWru7Y%3D 12506171
68. SP Menon SV Rajkumar M Lacy P Falco A Palumbo 2008 Thromboembolic events with lenalidomide-based therapy for multiple myeloma Cancer 112 7 1522 1528 1:CAS:528:DC%2BD1cXktlKrurw%3D 18278812
69. H Hurwitz L Fehrenbacher W Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435
70. FA Scappaticci JR Skillings SN Holden, et al. 2007 Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab J Natl Cancer Inst 99 1232 1239 17686822
71. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar National Cancer Institute of Canada Clinical Trials Group 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 1:CAS:528: DC%2BD2sXmvVWmsr0%3D 17452677
72. M Duvic R Talpur X Ni, et al. 2007 Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31 39 1:CAS:528:DC%2BD2sXivVyrt7g%3D 16960145 (Pubitemid 46053039)
73. M Verso G Agnelli 2003 Venous thromboembolism associated with long-term use of central venous catheters in cancer patients J Clin Oncol 21 3665 3675 14512399
74. M Verso G Agnelli S Bertoglio, et al. 2005 Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients J Clin Oncol 23 4057 4062 1:CAS:528:DC%2BD2MXmt1emurg%3D 15767643
75. AY Lee MN Levine G Butler, et al. 2006 Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer J Clin Oncol 24 1404 1408 16549834
76. J Bohlius J Wilson J Seidenfeld, et al. 2006 Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients J Natl Cancer Inst 98 708 714 1:CAS:528: DC%2BD28XkvVSrs70%3D 16705125
77. AA Khorana NM Kuderer E Culakova, et al. 2008 Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 4902 4907 1:CAS:528:DC%2BD1cXmtlaiur8%3D 18216292
78. SN Westin EN Skinner M Jonsson Funk, et al. 2007 Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer Gynecol Oncol 105 414 417 1:CAS:528:DC%2BD2sXksVOnu7w%3D 17250880
79. AA Khorana CW Francis E Culakova, et al. 2005 Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study Cancer 104 2822 2829 16284987
80. Simanek R. Vormittag R, Alguel G, Ay C, Dunkler D, Quehenberger P, Zielinski C, Jaeger U, Pabinger I (2007) A high platelet coung independently predicts venous thromboembolism in cancer patients. J Thromb Haemost 5:abstract PT497
81. A Falanga MN Levine R Consonni, et al. 1998 The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: results from a randomized trial Thromb Haemost 79 23 27 1:CAS:528:DyaK1cXmvVyltg%3D%3D 9459316
82. S Sallah A Husain V Sigounas, et al. 2004 Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy Clin Cancer Res 10 7238 7243 1:CAS:528: DC%2BD2cXpsVKltbk%3D 15534097
83. C Ay R Simanek R Vormittag, et al. 2008 High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) Blood 112 2703 2708 1:CAS:528:DC%2BD1cXht1Srtb7M 18539899
84. A Leizorovicz AT Cohen AG Turpie, et al. 2004 Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients Circulation 110 874 879 1:CAS:528:DC%2BD2cXmtlOqtb4%3D 15289368
85. AT Cohen BL Davidson AS Gallus, et al. 2006 Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial BMJ 332 325 329 1:CAS:528:DC%2BD28XitFSgsL0%3D 16439370
86. WH Geerts GF Pineo JA Heit, et al. 2004 Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 338S 400S 1:CAS:528:DC%2BD2cXptV2msbw%3D 15383478
87. AN Nicolaides J Fareed AK Kakkar HK Breddin SZ Goldhaber R Hull VV Kakkar JJ Michiels K Myers M Samama A Sasahara E Kalodiki 2006 Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence) Int Angiol 25 2 101 161
88. RD Hull GF Pineo RF Brant, et al. 2006 Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer Am J Med 119 1062 1072 1:CAS:528:DC%2BD28Xht1Kks7bL 17145251
89. GH Lyman AA Khorana A Falanga, et al. 2007 American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer J Clin Oncol 25 5490 5505 1:CAS:528: DC%2BD1cXnvVChtA%3D%3D 17968019 (Pubitemid 350232226)
90. M Mandala A Falanga F Roila 2008 Management of venous thromboembolism in cancer patients: ESMO clinical recommendations Ann Oncol 19 suppl 2 ii126 ii127 18456750
91. M Mandala A Falanga A Piccioli, et al. 2006 Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM) Crit Rev Oncol Hematol 59 194 204 1:STN:280:DC%2BD28rhtVGqsg%3D%3D 16837209
92. LD Wagman MF Baird CL Bennett, et al. 2006 Venous thromboembolic disease: clinical practice guidelines in oncology J Natl Compr Canc Netw 4 838 869 1:CAS:528:DC%2BD1cXmtFOqsrk%3D 17020664
93. MM Samama AT Cohen JY Darmon, et al. 1999 A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group N Engl J Med 341 793 800 1:CAS:528:DyaK1MXmtlGjsrs%3D 10477777
94. R Alikhan AT Cohen S Combe, et al. 2004 Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study Arch Intern Med 164 963 968 15136304
95. B Gärdlund 1996 Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases: The Heparin Prophylaxis Study Group Lancet 347 1357 1361 8637340
96. P Mismetti S Laporte-Simitsidis B Tardy, et al. 2000 Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular weight heparins: a meta-analysis of randomized clinical trials Thromb Haemost 83 14 19 1:CAS:528:DC%2BD3cXktlOhsQ%3D%3D 10669147
97. M Levine J Hirsh M Gent, et al. 1994 Double blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer Lancet 343 886 889 1:STN:280:DyaK2c7psFSitQ%3D%3D 7908358
98. D Deheinzelin AL Braga LC Martins, et al. 2006 Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil J Thromb Haemost 4 6 1266 1270 1:STN:280:DC%2BD283nvVeqsg%3D%3D 16706970
99. AY Lee 2009 Treatment of venous thromboembolism in cancer patients Best Pract Res Clin Haematol 22 93 101 1:CAS:528:DC%2BD1MXjt1agsLc%3D 19285276
100. TP Baglin DM Keeling HG Watson 2006 Guidelines on oral anticoagulation (warfarin): third edition-2005 update Br J Haematol 132 277 285 1:STN:280:DC%2BD28%2Fit1eqtg%3D%3D 16409292
101. G Palareti C Legnani A Lee, et al. 2000 A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy Thromb Haemost 84 805 810 1:CAS:528:DC%2BD3cXovFCjsLw%3D 11127860
102. P Prandoni AW Lensing A Piccioli, et al. 2002 Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 3484 3488 1:CAS:528:DC%2BD38XoslKmtLk%3D 12393647
103. BA Hutten MH Prins M Gent, et al. 2000 Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis J Clin Oncol 18 3078 3083 1:STN:280:DC%2BD3cvjvVSqtA%3D%3D 10963635
104. G Meyer Z Marjanovic J Valcke, et al. 2002 Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch Intern Med 162 1729 1735 1:CAS:528:DC%2BD38Xms1Sgu7k%3D 12153376
105. JB Segal MB Streiff LV Hofmann, et al. 2007 Management of venous thromboembolism: a systematic review for a practice guideline Ann Intern Med 146 211 222 17261856
106. HR Buller G Agnelli RD Hull, et al. 2004 Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 401S 428S 1:CAS:528:DC%2BD2cXptV2msbo%3D 15383479
107. C Kearon SR Kahn G Agnelli, et al. 2008 Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 454S 545S 1:CAS:528:DC%2BD1cXptVKhsrY%3D 18574272 (Pubitemid 351892971)
108. J Hirsh KA Bauer MB Donati, et al. 2008 Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 141S 159S 1:CAS:528:DC%2BD1cXptVKiu7w%3D 18574264 (Pubitemid 351892966)
109. HR Buller BL Davidson H Decousus, et al. 2003 Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism N Engl J Med 349 1695 1702 1:STN:280:DC%2BD3srgvF2nuw%3D%3D 14585937
110. TE Warkentin A Greinacher A Koster, et al. 2008 Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 340S 380S 1:CAS:528:DC%2BD1cXptVKhsro%3D 18574270
111. SI Noble MD Shelley B Coles, et al. 2008 Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis Lancet Oncol 9 577 584 18510989
112. ML Louzada H Majeed PS Wells 2009 Efficacy of low-molecular-weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials Thromb Res 123 837 844 1:CAS:528: DC%2BD1MXjvV2nur8%3D 18977517
113. H Decousus A Leizorovicz F Parent, et al. 1998 A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep vein thrombosis: Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group N Engl J Med 338 409 415 1:STN:280:DyaK1c7hslSltQ%3D%3D 9459643
114. PREPIC Study Group 2005 Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: The PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study Circulation 112 416 422
115. AA Khorana MV Rao 2007 Approaches to risk-stratifying cancer patients for venous thromboembolism Thromb Res 120 Suppl 2 S41 S50 18023712